Navigation Links
EntreMed Presents Initial Clinical Results for ENMD-2076
Date:2/9/2009

a A kinase and other oncogenic proteins. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 targets a defined set of kinases, including Flt-3 and FGFR3, which have been shown to play important roles in the pathology of hematological cancers.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing primarily ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in advanced cancers and multiple myeloma. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commissio
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... YORK , Nov. 24, 2014  Relmada Therapeutics, ... for the treatment of chronic pain, announced today that ... to present at the LD MICRO "MAIN Event" Micro-Cap ... will be held at the Luxe Sunset Bel Air ... Los Angeles, California . ...
(Date:11/24/2014)... Theater, LLC, announced today that their technology will be ... Europe,s first simulation center, The ... Planner (SRP) and the Surgical Navigation Advanced Platform (SNAP) ... navigation and augmented reality capabilities in the operating room ... Department of Neurosurgery at Mount Sinai Health System in ...
(Date:11/24/2014)... novembre 2014  Surgical Theater LLC ha ... esposta durante l,apertura in data 24 novembre ... la Fondazione IRCCS Istituto Neurologico Nazionale "C. ... (strumento di pianificazione chirurgica) e Surgical Navigation ... avanzata) saranno presentati in occasione dell,evento dedicato ...
Breaking Medicine Technology:Relmada Therapeutics To Present At LD MICRO Conference 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3La tecnologia di Surgical Theater in mostra in Italia all'apertura del centro Besta NeuroSim di Milano 2La tecnologia di Surgical Theater in mostra in Italia all'apertura del centro Besta NeuroSim di Milano 3La tecnologia di Surgical Theater in mostra in Italia all'apertura del centro Besta NeuroSim di Milano 4
... PLC ), a company focused on innovative cardiac ... the three,and twelve month periods ended December 31, 2007., ... with,$1,747,000 in the fourth quarter of 2006. The net ... $0.03 per diluted share, compared to net,income of $36,000, ...
... XYOTAX to be reviewed for PS2 first-line non-small cell lung cancer ... ... March 4 Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) announced ... Medicines Agency (EMEA) for,XYOTAX(TM) (paclitaxel poliglumex, CT-2103) for first-line treatment of,patients ...
Cached Medicine Technology:PLC Systems Reports Fourth Quarter 2007 Results 2PLC Systems Reports Fourth Quarter 2007 Results 3PLC Systems Reports Fourth Quarter 2007 Results 4PLC Systems Reports Fourth Quarter 2007 Results 5PLC Systems Reports Fourth Quarter 2007 Results 6Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM) 2Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM) 3Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM) 4
(Date:11/24/2014)... (PRWEB) November 24, 2014 Olaparib functions ... polymerase (PARP) and is one of the first PARP ... to creating some types of melanoma, and are often ... also sometimes gives their malignancies a exclusive weaknesses, as ... to fix their DNA and allow them to proceed ...
(Date:11/24/2014)... The Holiday Inn Westbury - Long ... Children's Association to donate various items consisting of ... other such items.The Association's program is aimed toward helping ... in nursing homes, assisted living facilities and nursing homes. ... being of seniors throughout the Long Island area. The ...
(Date:11/24/2014)... Raymond, Alberta (PRWEB) November 24, 2014 ... of people each day. They break up families, ... there is new hope for those that suffer,” ... “Ground-breaking scientific research is showing that our specialized ... , Hardy will appear on “Mind Over Matter”, ...
(Date:11/24/2014)... SafeHandles™ announced that they will be featured in ... airing via Discovery Channel. Dates and show times TBA. ... replaceable, and affordable germ protective device. This segment will ... adhesives to promote hand hygiene in high traffic and ... is the desire to make a positive impact in ...
(Date:11/24/2014)... Gersowitz Libo & Korek, P.C., a leading ... Tier recognition in the 2015 Edition of U.S. News-Best Lawyers ... a unique combination of quality law practice and breadth of ... honor and especially grateful to our clients whose continued support ... possible,” said Jeff S. Korek, senior partner at Gersowitz ...
Breaking Medicine News(10 mins):Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2
... Sept. 21 Roper Industries,Inc. (NYSE: ROP ) ... 2007, ended September 30, 2007, will be released after ... call to discuss these results,has been scheduled for 10:00 ... be accessed via webcast or by dialing +1 888-801-6506 ...
... SAN DIEGO, Sept. 21 ChemDiv, Inc. (San ... (CDRI, Moscow) is,undertaking a partnership with the Blokhin ... Medical Sciences, the US Department of Energy,(DOE), and ... novel small,molecule therapies for the prevention and treatment ...
... On Sept. 18, the,Michigan Association of Health Plans ... award reception at which eight Michigan HMOs received,the ... as these,are leading the way in serving participants ... "Michigan needs more,health care plans that expand outreach, ...
... are at high risk for preterm birth, giving them a ... babys chances of having serious lung problems after birth. , ... new study shows that repeat courses of corticosteroids are linked ... these mothers. , Our study shows that you get almost ...
... of studies shows big survival gains , THURSDAY, ... regimens of irinotecan, oxaliplatin, and molecular-targeted treatments are ... months longer than they did a few years ... say. , Researchers at the University of Ioannina ...
... 18, 2007 -- Recently, researchers at Iowa State University ... popular crop model. By zeroing in on early stages ... help improve yield predictions across a variety of environmental ... the September-October issue of Crop Science. , The Crop ...
Cached Medicine News:Health News:Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership 2Health News:Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership 3Health News:Eight Michigan HMOs, Two Providers, Take Top Honors for Quality Health Care 2Health News:Eight Michigan HMOs, Two Providers, Take Top Honors for Quality Health Care 3Health News:Multiple corticosteroid injections in pregnant women may increase cerebral palsy 2Health News:Experts Compare Colon Cancer Treatment Outcomes 2Health News:Simulating kernel production influences maize model accuracy 2
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
... For Anterior and Posterior segment surgeries ... using Ventury or Peristaltic Linear Aspiration. ... for specific cutting action. Easy to ... movement. Cutting speed-variable from 1- 600 ...
Medicine Products: